Partial
Partially Aligned
Patient Risk:
Medium
Summary
The response correctly aligns with the provided label for malignant hyperthermia treatment and calcium-release mechanism, but it introduces an unlabelled indication (severe muscle spasticity) and makes multiple safety/monitoring and long-term liver-risk claims that are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Dantrolene sodium is a prescription medicine used to treat malignant hyperthermia.
1 INDICATIONS AND USAGE (Treatment of malignant hyperthermia in conjunction with appropriate supportive measures)
Dantrolene sodium reduces skeletal muscle contraction.
12.1 Mechanism of Action (produces relaxation by affecting the contractile response of the muscle)
In malignant hyperthermia, dantrolene sodium helps counter abnormal muscle calcium release that drives the crisis.
12.1 Mechanism of Action (interfering with release of Ca++ from sarcoplasmic reticulum; reestablishes calcium equilibrium; reverses or attenuates malignant hyperthermia crisis changes)
Unsupported Statements
Dantrolene sodium is a prescription medicine used to treat severe muscle spasticity.
Not supported by the provided label excerpt; 1 INDICATIONS AND USAGE lists malignant hyperthermia treatment/prevention only.
In severe spasticity, dantrolene sodium lowers muscle overactivity that leads to stiffness and spasms.
Not supported by the provided label excerpt; no spasticity indication or related effects are described in the available sections.
Dantrolene sodium is administered urgently as an emergency treatment for malignant hyperthermia.
Only malignant hyperthermia treatment with appropriate supportive measures is shown; the provided excerpt does not state 'urgently' or 'emergency.'
Dantrolene sodium is administered according to a clinician’s dosing plan to control muscle symptoms in severe spasticity.
Not supported by the provided label excerpt; no spasticity dosing or symptom-control language is present.
Clinicians monitor patients for adverse reactions such as drowsiness and weakness with dantrolene sodium.
Monitoring/adverse reaction examples are not supported by the provided label excerpts (5 WARNINGS AND PRECAUTIONS and 6 ADVERSE REACTIONS content not provided).
With ongoing use, dantrolene sodium can involve longer-term risks including liver-related issues.
No liver-related longer-term risks are supported by the provided label excerpts (12.1 and 12.3 excerpts only).
Contradictions
High
AI Statement
Dantrolene sodium is a prescription medicine used to treat severe muscle spasticity.
Label Reference
1 INDICATIONS AND USAGE (only malignant hyperthermia treatment/prevention is listed in the provided excerpt)
Important Omissions
Dosage and administration details for malignant hyperthermia (e.g., regimen/timing) are not addressed by the AI claims; however, the provided label excerpts in this audit do not include section 2 DOSAGE AND ADMINISTRATION, so specific omissions relative to that section cannot be confirmed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The response includes an unlabelled indication (severe muscle spasticity) and makes additional safety/monitoring and liver-risk claims that are not supported by the provided label excerpts, which could mislead risk/usage expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Introduction of severe muscle spasticity as an indication and multiple unsupported safety/monitoring and liver-risk statements.
Suggested Improvement
Restrict claims to the label-supported indications (malignant hyperthermia treatment in conjunction with appropriate supportive measures and prevention in high-risk patients) and avoid asserting specific monitoring findings or long-term liver risks unless supported by provided label sections (e.g., 5 WARNINGS AND PRECAUTIONS/6 ADVERSE REACTIONS).